Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies
about
Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular TargetsDevelopment of Selective Covalent Janus Kinase 3 Inhibitors.Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.TS-Chemscore, a Target-Specific Scoring Function, Significantly Improves the Performance of Scoring in Virtual Screening.Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
P2860
Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of JAK3 with a nove ...... esponse in T-cell malignancies
@en
Inhibition of JAK3 with a nove ...... sponse in T-cell malignancies.
@nl
type
label
Inhibition of JAK3 with a nove ...... esponse in T-cell malignancies
@en
Inhibition of JAK3 with a nove ...... sponse in T-cell malignancies.
@nl
prefLabel
Inhibition of JAK3 with a nove ...... esponse in T-cell malignancies
@en
Inhibition of JAK3 with a nove ...... sponse in T-cell malignancies.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of JAK3 with a nove ...... esponse in T-cell malignancies
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2013.309
P577
2013-10-23T00:00:00Z